228 related articles for article (PubMed ID: 27167198)
1. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
2. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Mazor R; Eberle JA; Hu X; Vassall AN; Onda M; Beers R; Lee EC; Kreitman RJ; Lee B; Baker D; King C; Hassan R; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8571-6. PubMed ID: 24799704
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R; Onda M; Pastan I
Immunol Rev; 2016 Mar; 270(1):152-64. PubMed ID: 26864110
[TBL] [Abstract][Full Text] [Related]
5. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
6. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
[TBL] [Abstract][Full Text] [Related]
9. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
11. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM; Mazor R; Çuburu N; Pastan I
J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
[TBL] [Abstract][Full Text] [Related]
13. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
14. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Liu W; Onda M; Lee B; Kreitman RJ; Hassan R; Xiang L; Pastan I
Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11782-7. PubMed ID: 22753489
[TBL] [Abstract][Full Text] [Related]
16. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
17. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
18. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
19. Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.
Hu X; Zhang M; Zhang C; Long S; Wang W; Yin W; Cao Z
J BUON; 2016; 21(6):1374-1378. PubMed ID: 28039694
[TBL] [Abstract][Full Text] [Related]
20. Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
Wei J; Bera TK; Liu XF; Zhou Q; Onda M; Ho M; Tai CH; Pastan I
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3501-E3508. PubMed ID: 29581296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
